Skip to main content

Table 3 Peak creatine kinase and pre-discharge and follow-up CMR data

From: Infarct size following complete revascularization in patients presenting with STEMI: a comparison of immediate and staged in-hospital non-infarct related artery PCI subgroups in the CvLPRIT study

Variable Immediate CR
(n = 63)
Staged CR
(n = 30)
p
Peak CK (IU/L) 939 (627–1567) 1508 (938–2280) 0.05
Pre-discharge CMR    
Total Infarct Size (% LVM) 11.6 (6.8–18.2)
13.5 ± 11.4
19.7 (11.7–37.6)
22.6 ± 14.5
0.016
(0.012)*
Time from PPCI (days) 2.3 (1.7–3.2) 4.1 (2.7–5.4) <0.001
Infarct on LGE (%) 60 (95.2) 30 (100) 0.22
Patients with >1 acute infarct 7 (11.1) 9 (30.0) 0.024
IRA Infarct size (% LVM) 11.1 (5.4–17.4)
12.5 ± 10.0
19.1 (8.8–35.2)
20.9 ± 14.6
0.039
(0.05)*
Non-IRA Infarct size (% LVM) 0.9 ± 3.2 1.7 ± 3.6 0.11
(0.65)*
Total acute infarcts (% LVM) 11.6 (6.8–17.6)
13.0 ± 10.3
19.1 (10.2–37.1)
21.7 ± 14.8
0.006
(0.025)*
Area at risk (% LVM) 31.4 ± 12.5 33.1 ± 10.8 0.57
MSI§ (%) 61.7 (37.4–75.5) 35.1 (5.9–66.4) 0.008
(0.034)*
MVO present (n %) 34/63 (54.0) 21/30 (70.0) 0.14
MVO (% LVM) 0.07 (0.00–0.93) 0.44 (0.00–6.1) 0.032
(0.024)*
LVMI (g/m2) 52.5 (47.7–61.0) 51.5 (45.6–63.0) 0.55
LVEDVI (ml/m2) 89.9 (78.4–110.0) 89.7 (82.8–102.9) 0.43
LVEF (%) 47.4 ± 9.4 42.2 ± 10.2 0.019
Follow-up CMR n = 53 n = 26  
LVMI (g/m2) 45.2 (38.8–52.3) 47.4 (40.9–51.6) 0.71
LVEDVI (ml/m2) 92.5 (80.5–105.5) 93.9 (83.3–113.6) 0.28
LVEF (%) 50.9 ± 9.4 46.7 ± 8.9 0.06
Infarct on LGE (n,%) 51 (96.2) 26 (100) 0.32
Patients with >1 infarct (%) 9 (17.0) 9 (34.6) 0.08
IS (% LVM) 5.7 (2.4–10.4) 13.5 (4.6–23.3) 0.004
(0.044)*
  1. Data presented as n/N (%), mean ± SD or median (IQR)
  2. Abbreviations: CR complete revascularization, IRA infarct related artery, LVMI left ventricular mass index, LVEDVI left ventricular end-diastolic volume index, LVEF left ventricular ejection fraction, LGE late gadolinium enhancement, IS infarct size, MVO microvascular obstruction, MSI myocardial salvage index
  3. §Analyzable oedema imaging available in 76 % of patients in both groups
  4. *Adjusted for known predictors of IS (anterior MI, time to revascularization, diabetes, TIMI flow pre-PPCI) and important baseline variables significantly varying between the two groups (TIMI flow post-PPCI, SYNTAX score, dual antiplatelet therapy choice, glycoprotein inhibitor/bivalirudin use for N-IRA PCI)